Actively Recruiting
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Updated on 2024-10-21
80
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
CONDITIONS
Official Title
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- Diagnosis of advanced endometrial cancer or platinum-resistant ovarian cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival of at least 12 weeks
- Signed informed consent form
You will not qualify if you...
- Known uncontrolled or symptomatic central nervous system metastatic disease
- Prior anticancer therapy adverse events greater than grade 1, except alopecia and fatigue
- Inadequate organ or bone marrow function
- Pregnant or breastfeeding women
- Known allergies, hypersensitivity, or intolerance to SSGJ-707
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chongqing Cancer Hospital
Chongqing, China
Actively Recruiting
Research Team
Z
ZHOU, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here